|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zheng H, Zhan Y, Liu S, Lu J, Luo J, Feng
J and Fan S: The roles of tumor-derived exosomes in non-small cell
lung cancer and their clinical implications. J Exp Clin Cancer Res.
37:2262018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirsch FR, Suda K, Wiens J and Bunn PA Jr:
New and emerging targeted treatments in advanced non-small-cell
lung cancer. Lancet. 388:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhu L, Wang Z, Lin Y, Chen Z, Liu H, Chen
Y, Wang N and Song X: Sphingosine kinase 1 enhances the invasion
and migration of non-small cell lung cancer cells via the AKT
pathway. Oncol Rep. 33:1257–1263. 2015. View Article : Google Scholar
|
|
5
|
Maceyka M, Sankala H, Hait NC, Le Stunff
H, Liu H, Toman R, Collier C, Zhang M, Satin LS, Merrill AH Jr, et
al: SphK1 and SphK2, sphingosine kinase isoenzymes with opposing
functions in sphingolipid metabolism. J Biol Chem. 280:37118–37129.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adams DR, Pyne S and Pyne NJ: Sphingosine
kinases: Emerging structure-function insights. Trends Biochem Sci.
41:395–409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Meacci E and Garcia-Gil M: S1P/S1P
receptor signaling in neuromuscolar disorders. Int J Mol Sci.
20:E63642019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sukocheva OA, Furuya H, Ng ML, Friedemann
M, Menschikowski M, Tarasov VV, Chubarev VN, Klochkov SG, Neganova
ME, Mangoni AA, et al: Sphingosine kinase and
sphingosine-1-phosphate receptor signaling pathway in inflammatory
gastrointestinal disease and cancers: A novel therapeutic target.
Pharmacol Ther. 207:1074642020. View Article : Google Scholar
|
|
9
|
Andrieu G, Ledoux A, Branka S, Bocquet M,
Gilhodes J, Walzer T, Kasahara K, Inagaki M, Sabbadini RA,
Cuvillier O and Hatzoglou A: Sphingosine 1-phosphate signaling
through its receptor S1P5 promotes chromosome
segregation and mitotic progression. Sci Signal. 10:eaah40072017.
View Article : Google Scholar
|
|
10
|
Lee CF, Dang A, Hernandez E, Pong RC, Chen
B, Sonavane R, Raj G, Kapur P, Lin HY, Wu SR, et al: Activation of
sphingosine kinase by lipopolysaccharide promotes prostate cancer
cell invasion and metastasis via SphK1/S1PR4/matriptase. Oncogene.
38:5580–5598. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zheng X, Li W, Ren L, Liu J, Pang X, Chen
X, Kang, Wang J and Du G: The sphingosine
kinase-1/sphingosine-1-phosphate axis in cancer: Potential target
for anticancer therapy. Pharmacol Ther. 195:85–99. 2019. View Article : Google Scholar
|
|
12
|
Liu H, Ma Y, He HW, Zhao WL and Shao RG:
SPHK1 (sphingosine kinase 1) induces epithelial-mesenchymal
transition by promoting the autophagy-linked lysosomal degradation
of CDH1/E-cadherin in hepatoma cells. Autophagy. 13:900–913. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hillmer EJ, Zhang H, Li HS and Watowich
SS: STAT3 signaling in immunity. Cytokine Growth Factor Rev.
31:1–15. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Galoczova M, Coates P and Vojtesek B:
STAT3, stem cells, cancer stem cells and p63. Cell Mol Biol Lett.
23:122018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Johnson DE, O'Keefe RA and Grandis JR:
Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev
Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, van Boxel-Dezaire AH, Cheon H,
Yang J and Stark GR: STAT3 activation in response to IL-6 is
prolonged by the binding of IL-6 receptor to EGF receptor. Proc
Natl Acad Sci USA. 110:16975–16980. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao D, Pan C, Sun J, Gilbert C,
Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D,
et al: VEGF drives cancer-initiating stem cells through
VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene.
34:3107–3119. 2015. View Article : Google Scholar
|
|
18
|
Liang J, Nagahashi M, Kim EY, Harikumar
KB, Yamada A, Huang WC, Hait NC, Allegood JC, Price MM, Avni D, et
al: Sphingosine-1-phosphate links persistent STAT3 activation,
chronic intestinal inflammation, and development of
colitis-associated cancer. Cancer Cell. 23:107–120. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Egusquiaguirre SP, Yeh JE, Walker SR, Liu
S and Frank DA: The STAT3 target gene TNFRSF1A modulates the NF-κB
pathway in breast cancer cells. Neoplasia. 20:489–498. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Horibata S, Rice EJ, Zheng H, Mukai C, Chu
T, Marks BA, Coonrod SA and Danko CG: A bi-stable feedback loop
between GDNF, EGR1, and ERα contribute to endocrine resistant
breast cancer. PLoS One. 13:e01945222018. View Article : Google Scholar
|
|
21
|
Masuda M, Suzui M, Yasumatu R, Nakashima
T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB:
Constitutive activation of signal transducers and activators of
transcription 3 correlates with cyclin D1 overexpression and may
provide a novel prognostic marker in head and neck squamous cell
carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI
|
|
22
|
Xu L, Wang P, Feng X, Tang J, Li L, Zheng
X, Zhang J, Hu Y, Lan T, Yuan K, et al: SETD3 is regulated by a
couple of microRNAs and plays opposing roles in proliferation and
metastasis of hepatocellular carcinoma. Clin Sci (Lond).
133:2085–2105. 2019. View Article : Google Scholar
|
|
23
|
Merino D, Lok SW, Visvader JE and Lindeman
GJ: Targeting BCL-2 to enhance vulnerability to therapy in estrogen
receptor-positive breast cancer. Oncogene. 35:1877–1887. 2016.
View Article : Google Scholar
|
|
24
|
Liu L, Zhou XY, Zhang JQ, Wang GG, He J,
Chen YY, Huang C, Li L and Li SQ: LncRNA HULC promotes non-small
cell lung cancer cell proliferation and inhibits the apoptosis by
up-regulating sphingosine kinase 1 (SPHK1) and its downstream
PI3K/Akt pathway. Eur Rev Med Pharmacol Sci. 22:8722–8730.
2018.PubMed/NCBI
|
|
25
|
Fan Z, Jiang H, Wang Z and Qu J:
Atorvastatin partially inhibits the epithelial-mesenchymal
transition in A549 cells induced by TGF-β1 by attenuating the
upregulation of SphK1. Oncol Rep. 36:1016–1022. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schwartz LH, Seymour L, Litiere S, Ford R,
Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, et
al: RECIST 1.1 Standardisation and disease-specific adaptations:
Perspectives from the RECIST working group. Eur J Cancer.
62:138–145. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
28
|
Tang Z, Kang B, Li C, Chen T and Zhang Z:
GEPIA2: An enhanced web server for large-scale expression profiling
and interactive analysis. Nucleic Acids Res. 47(W1): W556–W560.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lan T, Liu W, Xie X, Xu S, Huang K, Peng
J, Shen X, Liu P, Wang L, Xia P and Huang H: Sphingosine kinase-1
pathway mediates high glucose-induced fibronectin expression in
glomerular mesangial cells. Mol Endocrinol. 25:2094–2105. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen J, Tang H, Sysol JR, Moreno-Vinasco
L, Shioura KM, Chen T, Gorshkova I, Wang L, Huang LS, Usatyuk PV,
et al: The sphingosine kinase 1/sphingosine-1-phosphate pathway in
pulmonary arterial hypertension. Am J Respir Crit Care Med.
190:1032–1043. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hardy E, Hardy-Sosa A and Fernandez-Patron
C: MMP-2: Is too low as bad as too high in the cardiovascular
system? Am J Physiol Heart Circ Physiol. 315:H1332–H1340. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lo UG, Bao J, Cen J, Yeh HC, Luo J, Tan W
and Hsieh JT: Interferon-induced IFIT5 promotes
epithelial-to-mesenchymal transition leading to renal cancer
invasion. Am J Clin Exp Urol. 7:31–45. 2019.PubMed/NCBI
|
|
33
|
Wu X, Wu Q, Zhou X and Huang J: SphK1
functions down-stream of IGF-1 to modulate IGF-1-induced EMT,
migration and paclitaxel resistance of A549 cells: A preliminary in
vitro study. J Cancer. 10:4264–4269. 2019. View Article : Google Scholar :
|
|
34
|
Yin S, Miao Z, Tan Y, Wang P, Xu X, Zhang
C, Hou W, Huang J and Xu H: SPHK1-induced autophagy in peritoneal
mesothelial cell enhances gastric cancer peritoneal dissemination.
Cancer Med. 8:1731–1743. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Acharya S, Yao J, Li P, Zhang C, Lowery
FJ, Zhang Q, Guo H, Qu J, Yang F, Wistuba II, et al: Sphingosine
kinase 1 signaling promotes metastasis of triple-negative breast
cancer. Cancer Res. 79:4211–4226. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shen Z, Feng X, Fang Y, Li Y, Li Z, Zhan
Y, Lin M, Li G, Ding Y and Deng H: POTEE drives colorectal cancer
development via regulating SPHK1/p65 signaling. Cell Death Dis.
10:8632019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Song L, Xiong H, Li J, Liao W, Wang L, Wu
J and Li M: Sphingosine kinase-1 enhances resistance to apoptosis
through activation of PI3K/Akt/NF-κB pathway in human non-small
cell lung cancer. Clin Cancer Res. 17:1839–1849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang L, Hu H, Deng Y and Bai Y: Role of
SPHK1 regulates multi-drug resistance of small cell lung cancer and
its clinical significance. Zhongguo Fei Ai Za Zhi. 17:769–777.
2014.In Chinese. PubMed/NCBI
|
|
39
|
Zhang G, Zheng H, Zhang G, Cheng R, Lu C,
Guo Y and Zhao G: MicroRNA-338-3p suppresses cell proliferation and
induces apoptosis of non-small-cell lung cancer by targeting
sphingosine kinase 2. Cancer Cell Int. 17:462017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Y, Hu T, Chen T, Yang T, Ren H and Chen
M: Combination treatment of FTY720 and cisplatin exhibits enhanced
antitumour effects on cisplatin-resistant non-small lung cancer
cells. Oncol Rep. 39:565–572. 2018.
|
|
41
|
Xu CY, Liu SQ, Qin MB, Zhuge CF, Qin L,
Qin N, Lai MY and Huang JA: SphK1 modulates cell migration and
EMT-related marker expression by regulating the expression of p-FAK
in colorectal cancer cells. Int J Mol Med. 39:1277–1284. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Marvaso G, Barone A, Amodio N, Raimondi L,
Agosti V, Altomare E, Scotti V, Lombardi A, Bianco R, Bianco C, et
al: Sphingosine analog fingolimod (FTY720) increases radiation
sensitivity of human breast cancer cells in vitro. Cancer Biol
Ther. 15:797–805. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen XF, Guo JF, Xu JF, Yin SH and Cao WL:
MiRNA-206 inhibits proliferation of renal clear cell carcinoma by
targeting ZEB2. Eur Rev Med Pharmacol Sci. 23:7826–7834.
2019.PubMed/NCBI
|
|
44
|
Wang Z, Tang T, Wang S, Cai T, Tao H,
Zhang Q, Qi S and Qi Z: Aloin inhibits the proliferation and
migration of gastric cancer cells by regulating NOX2-ROS-Mediated
pro-survival signal pathways. Drug Des Devel Ther. 14:145–155.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhao S, Guo J, Zhao Y, Fei C, Zheng Q, Li
X and Chang C: Chidamide, a novel histone deacetylase inhibitor,
inhibits the viability of MDS and AML cells by suppressing
JAK2/STAT3 signaling. Am J Transl Res. 8:3169–3178. 2016.PubMed/NCBI
|
|
46
|
Guanizo AC, Fernando CD, Garama DJ and
Gough DJ: STAT3: A multifaceted oncoprotein. Growth Factors.
36:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Lewis KM, Bharadwaj U, Eckols TK, Kolosov
M, Kasembeli MM, Fridley C, Siller R and Tweardy DJ: Small-molecule
targeting of signal transducer and activator of transcription
(STAT) 3 to treat non-small cell lung cancer. Lung Cancer.
90:182–190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kanda N, Seno H, Konda Y, Marusawa H,
Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y,
et al: STAT3 is constitutively activated and supports cell survival
in association with survivin expression in gastric cancer cells.
Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kijima T, Niwa H, Steinman RA, Drenning
SD, Gooding WE, Wentzel AL, Xi S and Grandis JR: STAT3 activation
abrogates growth factor dependence and contributes to head and neck
squamous cell carcinoma tumor growth in vivo. Cell Growth Differ.
13:355–362. 2002.PubMed/NCBI
|
|
50
|
Lei Z, Duan H, Zhao T, Zhang Y, Li G, Meng
J, Zhang S and Yan W: PARK2 inhibits osteosarcoma cell growth
through the JAK2/STAT3/VEGF signaling pathway. Cell Death Dis.
9:3752018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wu Z, Liu J, Hu S, Zhu Y and Li S:
Serine/Threonine kinase 35, a target gene of STAT3, regulates the
proliferation and apoptosis of osteosarcoma cells. Cell Physiol
Biochem. 45:808–818. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhu H, Chang LL, Yan FJ, Hu Y, Zeng CM,
Zhou TY, Yuan T, Ying MD, Cao J, He QJ and Yang B: AKR1C1 activates
STAT3 to promote the metastasis of non-small cell lung cancer.
Theranostics. 8:676–692. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Nazouri AS, Asadpour O, Dabiri S,
Pourseyedi B, Lashkarizadeh MR and Zianalinejad H: High expression
of sphingosine kinase 1 in estrogen and progesterone
receptors-negative breast cancer. Iran J Pathol. 12:218–224. 2017.
View Article : Google Scholar
|
|
54
|
Sankala HM, Hait NC, Paugh SW, Shida D,
Lépine S, Elmore LW, Dent P, Milstien S and Spiegel S: Involvement
of sphingosine kinase 2 in p53-independent induction of p21 by the
chemo-therapeutic drug doxorubicin. Cancer Res. 67:10466–10474.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu SQ, Xu CY, Wu WH, Fu ZH, He SW, Qin MB
and Huang JA: Sphingosine kinase 1 promotes the metastasis of
colorectal cancer by inducing the epithelial-mesenchymal transition
mediated by the FAK/AKT/MMPs axis. Int J Oncol. 54:41–52. 2019.
|
|
56
|
Nagahashi M, Yamada A, Katsuta E, Aoyagi
T, Huang WC, Terracina KP, Hait NC, Allegood JC, Tsuchida J, Yuza
K, et al: Targeting the SphK1/S1P/S1PR1 axis that links obesity,
chronic inflammation, and breast cancer metastasis. Cancer Res.
78:1713–1725. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Loh KC, Leong WI, Carlson ME, Oskouian B,
Kumar A, Fyrst H, Zhang M, Proia RL, Hoffman EP and Saba JD:
Sphingosine-1-phosphate enhances satellite cell activation in
dystrophic muscles through a S1PR2/STAT3 signaling pathway. PLoS
One. 7:e372182012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jin Z, Li H, Hong X, Ying G, Lu X, Zhuang
L and Wu S: TRIM14 promotes colorectal cancer cell migration and
invasion through the SPHK1/STAT3 pathway. Cancer Cell Int.
18:2022018. View Article : Google Scholar : PubMed/NCBI
|
